In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wall Street’s Take On Health Care Exchanges

Executive Summary

Health care exchanges for expanding insurance coverage as part of the Affordable Care Act will open in time to meet the law’s January 1 deadline, but their “robustness” and ease of use, at least initially, may be questionable, a panel of experts tells Wall Street.

You may also be interested in...



Why ACA Is A Boon For Health Care, Hospitals: An Interview With Tom Scully

Ex-CMS administrator Thomas Scully, who has played an important role in moving forward some key federal health policy initiatives, including Medicare Part D, is optimistic about the Affordable Care Act’s impact on several sectors of health care, notably hospitals, and biopharma – in contrast to the industry’s general uncertainty and nervousness around implementation.

Deals Of The Week Ponders The ACA

In a slow week for pharma deals, standouts included GSK’s wrap up with MorphoSys for a mid-stage rheumatoid arthritis drug, Pfizer’s deal to gain access to novel kinds of antibody drug-conjugates through platform company CytomX, and the first microbiome deal between a big pharma (Janssen) and a start-up, Second Genome.

Medicaid Expansion: Glass Half Full for Biopharma

Most health reform watchers have been tracking state votes on Medicaid expansion as a sort of scorecard on whether Obama Administration is winning or losing in health care reform. Push back from the states is making news now, but for biopharma sponsors, even a glass half full is a positive—and the long-term outlook is even brighter.

Related Content

Topics

UsernamePublicRestriction

Register

SC142496

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel